Why this trial matters: First large Phase III evidence of biopsy-confirmed histologic benefit with a metabolic drug in MASH Demonstrates semaglutides impact beyond weight loss to disease-modifying liver effects Supports expanding GLP-1 therapeutics into liver disease care amid a high unmet need Ianalumab Meets Endpoints in Phase III Sjgrens Disease Trials (NEPTUNUS-1 & 2) Novartis reported that both Phase III studies of ianalumab achieved their primary endpoints in patients with Sjgrens disease, offering the first targeted therapy with statistically significant disease activity reduction in this chronic autoimmune disorder
A.Robert, J.E.Nazamis, C.Lancaster, J.N.Badolementi, Digestion, 1974
Its not just about recovering faster after workouts, though thats a huge part of it
This imbalance leads to cellular damage and eventually cell death and causes chronic illness, aging, and disfunction in the body
During biodegradation, microorganisms that colonize the surface of the GAC, forming a biofilm, metabolize organic contaminants
